
Market: Hong Kong Stock Code: 2137.HK ISIN: KYG1645A1094 Industry: Biotechnology

Brii Biosciences (stock code: 2137.HK) is a biotechnology company developing therapies to address some of the world's most common public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice.



Mar

Share Data	27/09/2024
Currency HKD	Volume 2,698,000
Previous Close 1.17	Number of Shares(mil) 730.44
Change (%) 7.34	Share Market Cap (mil) 854.61

# **Pipeline**

Infectious Disease Programs							
Indication	Program	Preclinical	IND	Phase 1	Phase 2	Phase 3	
Hepatitis B Treatment <sup>(1)</sup> Prevention	BRII-179						
	Elebsiran <sup>(2)</sup>						
	Tobevibart <sup>(3)</sup>						
	PreHevbri <sup>TM(4)</sup>						
HIV	BRII-732						
	BRII-753						
MDR/XDR Gram- negative Bacterial Infections	BRII-693				•		
NTM Lung Disease	Epetraborole <sup>(5)</sup>				•		

#### Central Nervous System Disease Programs Indication Program Preclinical IND Phase 1 Phase 2 Phase 3 NDA/BLA Commercial Brii Rights **Partners** Internally PPD BRII-296 Global discovered Anxiety & Internally Depressive BRII-297 Global discovered Disorder

- \* Greater China Mainland China, Macau, Hong Kong and Taiwan
- (1) The Phase 2 combination clinical trials conducted by Brii Bio:
- · Elebsiran + BRII-179
- · BRII-179 + PEG-IFNa
- · ENSURE: Elebsiran ± PEG-IFNa
- (2) Elebsiran was previously known as BRII-835 or VIR-2218.
- (3) Tobevibart was previously known as BRII-877 or VIR-3434. The Phase 2 clinical trials have been conducted by Vir.
- (4) VBI launched PreHevbrio/PreHevbri in the United States, Canada, European Union, European Economic Area, the United Kingdom, and Israel. Brii Bio acquired exclusive rights for APAC countries (ex-Japan) in July 2023.
- (5) Epetraborole is also known as BRII-658. To this date, the development and clinical trials have been conducted by AN2.

#### **Board of Directors**

	Audit and Risk Committee	Nomination Committee	Remuneration Committee	Strategic Committee	Executive Directors	Non-executive Directors	Independent Non-executive Directors
Dr. Zhi Hong		_					
Dr. Ankang Li				<u></u>	<u> </u>		
Dr. Martin J. Murphy Jr.		•					<b>.</b>
Ms. Grace Hui Tang			•				•
Mr. Yiu Wa Alec Tsui	•		•				<b>.</b>
Mr. Gregg Huber Alton		*		•			<b>.</b>
Dr. Taiyin Yang				•			<b>.</b>

Chairperson 💄 Membe

CVs of the Board Members



Susannah Cantrell, Ph.D. Chief Business Officer



Eleanor (Ellee) de Groot,

Chief Technology Officer



Zhi Hong, Ph.D. **Executive Director** Chairman of the Board and Chief Executive Officer



Brian Alvin Johns, Ph.D. Chief Scientific Officer



Ankang Li, Ph.D., J.D., CFA Executive Director, Chief Strategy and Financial Officer Chief Executive Officer of TSB Therapeutics

Total assets



David Margolis, M.D., MPH **Chief Medical Officer** 



Karen D. Neuendorff Chief People Officer and Head of Human Resources

3,611,699

3,391,849



Qing Zhu, Ph.D. Head of China R&D

CVs of the Corporate Executive Team Members


2023

3,198,251

#### **Financial Highlights BRII-B (RMB'000)** 2021 2022 **Operating Results** Other income 99,032 107,857 163,728 Other gains and losses 45,062 (12,289)252,402

Financial Position			
Loss for the year	(4,191,084)	(489,781)	(184,370)
Listing expenses	(32,137)	-	-
Finance costs	(1,175)	(851)	(494)
Fair value loss on financial liabilities at FVTPL	(3,598,847)	-	-
Administrative expenses	(208,404)	(168,629)	(196,499)
Research and development expenses	(494,615)	(440,634)	(402,705)

Total liabilities	300,443	234,352	125,869
Total equity (deficits)	3,311,256	3,157,497	3,072,382
Selected Items from Consolidated Cash Flow Statement			
Net cash used in operating activities	(879,457)	(496,279)	(594,014)
Net cash used in investing activities	(475,756)	(1,433,168)	(104,350)
Net cash from financing activities	3,230,134	(3,042)	(10,977)
Net increase in cash and cash equivalents	1,874,921	(1,932,489)	(709,341)
Cash and cash equivalents at end of the year	2,855,093	1,190,572	489,650
Key indicators			
Loss per share - Basic and diluted (RMB)	(9.48)	(0.67)	(0.24)
Current Ratio	1.22	1.34	2.21



**Brii Biosciences Limited** 

# **U.S. OFFICES**

# **Durham, NC, United States**

WeWork, Suite 05-110, One City Center, 110 Corcoran Street, Durham, NC 27701, United States

## San Mateo, CA, United States

WeWork, Suite 02-114, 1825 South Grant Street, San Mateo, CA 94402, United States

Email:ir@briibio.com

# **CHINA OFFICES**

## Beijing, China

3rd Floor, Building #7, Zhongguancun, Dongsheng International Science Park, No. 1 North Yongtaizhuang Road, Haidian District, Beijing 100192, P.R.China

#### Shanghai, China

Room 805, 8th Floor, Kerry Parkside, No.1155 Fangdian Road, Pudong, District, Shanghai 201204, P.R.China



Supplied by © EUROLAND IR®
For terms of use and data vendors information,
see Disclaimer | Cookie policy